Atogepant (Aquipta®). HTA ID: 23039

Assessment Status Rapid Review Complete
HTA ID 23039
Drug Atogepant
Brand Aquipta®
Indication Prophylaxis of migraine in adults who have at least 4 migraine days per month
Assessment Process
Rapid review commissioned 10/07/2023
Rapid review completed 21/08/2023
Rapid review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of atogepant for this indication on the basis of the proposed price relative to currently available therapies. *

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.